Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Concentration Risk %

Concentration Risk % at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
93.1%-5.3pp
Heartland Express logo
Heartland ExpressHTLD
32%+6.0pp
Enovix Corporation logo
Enovix CorporationENVX
83%+36.0pp
Weis Markets logo
Weis MarketsWMK
100%0.0pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
36%+7.0pp
Strattec Security logo
Strattec SecuritySTRT
0.5%0.0pp

Segments

By product

See full
Smallpox MCM39%—
Naloxone products33%—
Anthrax MCM17%—
Other Products11%—
Other Commercial Products0%—

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×—
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%—

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×